inventor(s): LEE Appln. No.:

80 Series Code ↑

966,233 Serial No.

Client Ref

Filed:

November 7, 1997

Title: GDF-1 GENE (as amended)

Asst. Commissioner of Patents Washington, D.C. 20231

Sir:

Group Art Unit 1818 Examiner: M. Allen Atty Dat. PMS 241800

(Our Deposit Account No. 03-3975)

М#

(Our Order No.

20263

Date:

April 24, 1998

LPR 2 4 1933

REPLY/AMENDMENT/LETTER

This is a reply/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated hereinto by reference and the signature below is treated as the signature to the attachment in absence of a signature thereto.

FEE REQUIREMENTS FOR CLAIMS AS AMENDED

"Small Entity" statement(s) filed							
☑ previously ☐ herewith (No.)	Claims remaining after amendment	Highest number previously paid for		Present Extra	Large/Small Entity	Additional Fee	Fee Code
2. Total Effective Claims	15	**minus	20	0	x \$22/\$11 =	1+0	103/203
3. Independent Claims	3	***minus	3	0	x \$82/\$41 =	+0	102/202
4. If amendment enters <u>proper</u> multiple dependent claim(s) into this application for <u>first</u> time (leave <u>blank</u> if this is a <u>reissue</u> application)						+	104/204
6. Petition is hereby made to exten	(1 mo)		\$110/\$55 =	T		16	
due date to cover the date this resp	•	mos)	\$400/\$200 =	+		115/215	
for which the requisite fee is attached	' ' '		\$950/\$475 =			116/216 117/217	
7. Enter any previous extension fee paid since above original due date and subtract							217
8.						+	
9. If <u>Terminal Disclaimer</u> attached, add Rule 20(d) official fee + \$110/\$55 =						+	148/248
or if Rule 97(d) Petition						+	126 122
1 + \$790/395 =						+	146/246
12. No. of additional inventions for examination per Rule 129(b)						+	149/249
13. Petition fee for						+	
14. TOTAL FEE ENCLOSED =						\$0	
15. *If the entry in this space is less than entry in next space the "Present Extro" rocult is "0"							

the entry in this space is less than entry in next space, the "Present Extra" result is "0".

16. **If the "Highest number previously paid for" in this space is less than 20, write "20" in this space.

17. ***If the "Highest number previously paid for" in this space is less than 3, write "3" in this space.

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown in the heading hereof, for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal sheet is filed.

Query: Is appeal deadline now? If so, file Notice of Appeals separately.

Pillsbury Madison & Sutro LLP Intellectual Property Group

By Atty: Paul N. Kokulis

Reg. No. 16,773

Fax:

Tel:

Ninth Floor East Tower Washington, D.C. 20005-3918

1100 New York Avenue, N.W.

Sig:

(202) 822-0944 (202) 861-3503

Tel: (202) 861-3000 Atty/Sec: PNK/GRT/maf

NOTE: File this cover sheet in duplicate with PTO receipt (PAT-103A) and attachments

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

LEE

Appln. No. 08/966,233

Group Art Unit: 1818

Filed: November 7, 1997

Examiner: M. Allen

FOR: GDF-1 GENE (as amended)

April 24, 1998

SECOND PRELIMINARY AMENDMENT

Honorable Commissioner of Patents and Trademarks Washington, D.C. 20231

LPR 2 4 893

Sir:

Entry and consideration of the following amendment and remarks prior to examination are respectfully requested.

IN THE TITLE:

Please replace the title of the application wherever it appears with --GDF-1 Gene--.

REMARKS

Claims 3, 11-15, 22 and 24-31 are pending.

The attached Rule 132 Declaration by Ted Ebendal along with supporting materials shows that GDF-1 protein potentiates the effect of neurotrophin-3 protein on neuronal fibre outgrowth. Such potentiation activity is also found for members of the TGF- β superfamily, and it directly supports a finding of similarity in biological activities between GDF-1

5/22/98

LEE - Appln. No. 08/966,233

and other members of the TGF- β superfamily (see pages 12-14 of the present specification). Applicant submits that such evidence refutes the allegations made by the Examiner that the specification does not teach a practical use for GDF-1.

A favorable action on the merits is earnestly requested. If any further information is required, the Examiner is invited to contact the undersigned.

Respectfully submitted,

Cushman Darby & Cushman Intellectual Property Group of PILLSBURY MADISON & SUTRO, L.L.P.

Paul N. Kokulis

Reg. No. 16,773

Telephone: (202) 861-3503 Facsimile: (202) 822-0944

1100 New York Avenue, N.W. Ninth Floor, East Tower Washington, D.C. 20005-3918 Phone: (202) 861-3000